Through data collection and process review we identified lengthy waiting lists, patients not attending appointments and patient uncertainty regarding allergy testing as our greatest challenges.
A4d reviewed current processes and patient information looking at ways to improve. The patient Appointment letter was reviewed and unnecessary information, including a map of the Hospital, removed. The revised letter provided clear, concise information and the inclusion of the ASCIA allergy testing patient information sheet. The letter stipulated that the extracts could not be made unless the appointment was confirmed by the patient at least 1 week prior to their appointment. The patient received the letter 4 weeks prior to their appointment date and once confirmed received an appointment reminder via text message the day prior to their appointment.
Patient attendance data collected to date demonstrates a 29% improvement rate. We will continue to review our practices to ensure we meet current best practice.
By making these small changes there is demonstrated evidence of having a big impact on attendance rates, waiting lists and patient knowledge of allergy testing. Introduction: Here we report a case of a 47 year old male with recurrent anaphylaxis to honey bee venom, refractory to the use of sub-cutaneous omalizumab administered concurrently with his hymenoptera venom immunotherapy (hVITx).
Case description: In 2016, our patient was initiated on hVITx in the Day Procedure Unit at Fiona Stanley Hospital after an episode of hypotensive anaphylaxis with decreased consciousness, loss of bowel control and vomiting after a field sting.
His baseline mast cell tryptase was elevated at 27.1 mcg/L and honey bee venom sIgE was 13.10 kU/L. There were no clinical or other laboratory features of systemic mastocytosis and no further investigation was recommended following Haematology review.
Our patient had hypotensive anaphylaxis on the 3 rd injection of hVITx (5mcg) on day 1 of the procedure, with a similar reaction 1 week later when reinitiating hVITx despite premedication with prednisolone and antihistamine.
One week prior to a third attempt at desensitization, 300mg of omalizumab was administered via sub-cutaneous injection resulting in a successful induction of hVITx.
A maintenance dose of 100mcg venom was reached while continuing omalizumab at a reduced dose, however there was a recurrent anaphylaxis to hVITx on a trial cessation of omalizumab.
Further investigation identified a small population of mast cells by flow cytometry from bone marrow aspirate and positive D816V mutation on peripheral blood.
Conclusion:
To date, this gentleman has good response to concurrent sub-cutaneous omalizumab 150mg with hVITx. He has however, developed anaphylaxis to his hVITx with a trial cessation of omalizumab. Further consideration is currently being given to treatment for an underlying mast cell disorder by the Haematology team. The question of whether concurrent use of omalizumab has interfered with the efficacy of hVITx in this patient remains unresolved. There is increased patient awareness of SCIg as a treatment option. Informal patient feedback has been positive. Formal evaluation is under development for patients and health services. Identifying ongoing challenges and strategies to achieve sustainability is continuing.
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Conclusion:
Work is still required to embed SCIg as a treatment option by health services, however, early results indicate patients want a choice, and they are choosing SCIg. 
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